VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex's Cystic Fibrosis Combo Gets Extended EU Nod For Treating Children

01/11/2022 | 03:56am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION 0.43% 56.07 Delayed Quote.-17.45%
VERTEX PHARMACEUTICALS 1.23% 255.45 Delayed Quote.16.33%
VERTEX, INC. 3.04% 11.53 Delayed Quote.-27.35%
All news about VERTEX PHARMACEUTICALS
05/19Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors
AQ
05/18VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (for..
AQ
05/18Suketu Upadhyay Elected to Vertex Board of Directors
BU
05/18Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director
CI
05/17Vertex Pharmaceuticals Pledges $50 Million to Health Equity
MT
05/17Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey L..
BU
05/17Vertex Pharmaceuticals Incorporated Announces Further Expansion in the Boston Seaport A..
CI
05/17Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
BU
05/09UBS Adjusts Vertex Pharmaceuticals Price Target to $321 From $322, Maintains Buy Rating
MT
05/06VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..
AQ
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2022 8 585 M - -
Net income 2022 3 253 M - -
Net cash 2022 10 823 M - -
P/E ratio 2022 20,2x
Yield 2022 -
Capitalization 65 333 M 65 333 M -
EV / Sales 2022 6,35x
EV / Sales 2023 5,48x
Nbr of Employees 3 900
Free-Float 99,6%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 255,45 $
Average target price 294,18 $
Spread / Average Target 15,2%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS16.33%65 333
GILEAD SCIENCES, INC.-12.86%79 360
REGENERON PHARMACEUTICALS, INC.4.06%70 805
WUXI APPTEC CO., LTD.-19.12%41 354
BIONTECH SE-34.88%40 796
GENMAB A/S-18.90%19 884